Unbound MEDLINE

Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex. American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] Journal article

 
TitleAssociation of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex.
Author(s)Miller JE, Kovesdy CP, Nissenson AR, Mehrotra R, Streja E, Van Wyck D, Greenland S, Kalantar-Zadeh K 
InstitutionHarold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance; Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA.
SourceAm J Kidney Dis 2009 Oct 21.
AbstractBACKGROUND: The association of survival with characteristics of thrice-weekly hemodialysis (HD) treatment, including dose or duration of treatment, has not been completely elucidated, especially in different race and sex categories.
STUDY DESIGN: We examined associations of time-averaged and quarterly varying (time-dependent) delivered HD dose and treatment time and 5-year (July 2001-June 2006) survival.
SETTING & PARTICIPANTS: 88,153 thrice-weekly-treated HD patients from DaVita dialysis clinics. PREDICTORS: HD treatment dose (single-pool Kt/V) and treatment time. OUTCOMES & OTHER
MEASUREMENTS: 5-Year mortality.
RESULTS: Thrice-weekly treatment time < 3 hours (but >/= 2.5 hours) per HD session compared with >/= 3.5 hours (but < 5 hours) was associated with increased death risk independent of Kt/V dose. The greatest survival gain of higher HD dose was associated with a Kt/V approaching the 1.6-1.8 range, beyond which survival gain was minimal, nonexistent, or even tended to reverse in African American men and those with 4-5 hours of HD treatment. In non-Hispanic white women, Kt/V > 1.8 continued to show survival advantage trends, especially in time-dependent models.
LIMITATIONS: Our results may incorporate uncontrolled confounding. Achieved Kt/V may have different associations than targeted Kt/V.
CONCLUSIONS: HD treatment dose and time appear to have different associations with survival in different sex or race groups. Randomized controlled trials may be warranted to examine these associations across different racial and demographic groups.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19853336
  
Advertise on this site.